Identification of a β1/β2-Specific Sulfonamide Proteasome Ligand by Crystallographic Screening

Indolo-Phakellins as β5-Specific Noncovalent Proteasome Inhibitors

(2015) Philipp Beck et al.   ANGEWANDTE CHEMIE-INTERNATIONAL EDITION

Bortezomib-Resistant Mutant Proteasomes: Structural and Biochemical Evaluation with Carfilzomib and ONX 0914

(2015) Eva M. Huber et al.   STRUCTURE

Crystal Structure of the Human 20S Proteasome in Complex with Carfilzomib

(2015) Wayne Harshbarger et al.   STRUCTURE

Selective Inhibition of the Immunoproteasome by Ligand-Induced Crosslinking of the Active Site

(2014) Christian Dubiella et al.   ANGEWANDTE CHEMIE-INTERNATIONAL EDITION

Structure-Based Design of β1i or β5i Specific Inhibitors of Human Immunoproteasomes

(2014) Gerjan de Bruin et al.   JOURNAL OF MEDICINAL CHEMISTRY

Inhibitors for the Immuno- and Constitutive Proteasome: Current and Future Trends in Drug Development

(2012) Eva Maria Huber et al.   ANGEWANDTE CHEMIE-INTERNATIONAL EDITION

Immuno- and Constitutive Proteasome Crystal Structures Reveal Differences in Substrate and Inhibitor Specificity

(2012) Eva M. Huber et al.   CELL

Proteasome Inhibitors: An Expanding Army Attacking a Unique Target

(2012) Alexei F. Kisselev et al.   CHEMISTRY & BIOLOGY

Optimization of a series of dipeptides with a P3 β-neopentyl asparagine residue as non-covalent inhibitors of the chymotrypsin-like activity of human 20S proteasome

(2012) Christopher Blackburn et al.   MedChemComm

Hydroxyureas as Noncovalent Proteasome Inhibitors

(2011) Nerea Gallastegui et al.   ANGEWANDTE CHEMIE-INTERNATIONAL EDITION

Novel Organic Proteasome Inhibitors Identified by Virtual and in Vitro Screening

(2009) Nicolas Basse et al.   JOURNAL OF MEDICINAL CHEMISTRY

Proteasome Inhibitors in Cancer Therapy: Lessons from the First Decade

(2008) R. Z. Orlowski et al.   CLINICAL CANCER RESEARCH

Mechanisms of proteasome inhibitor action and resistance in cancer

(2008) David J. McConkey et al.   DRUG RESISTANCE UPDATES